Welcome to our dedicated page for TILRAY BRANDS SEC filings (Ticker: TLRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tilray Brands SEC documents means navigating cannabis-specific fair-value accounting, multi-country licensing rules, and shifting IFRS-to-GAAP footnotes. If you have ever scrolled a 300-page annual report searching for biological asset valuations or the latest convertible-note disclosure, you know the challenge.
Our platform resolves that problem. Stock Titan delivers AI-powered summaries that turn a dense Tilray Brands annual report 10-K simplified into clear takeaways, highlights cash-flow drivers inside every Tilray Brands quarterly earnings report 10-Q filing, and flags Tilray Brands 8-K material events explained minutes after they hit EDGAR. AG真人官方-time alerts show Tilray Brands Form 4 insider transactions real-time, so you can monitor each executive purchase or sale without hunting through PDFs.
What can you extract?
- Track harvest yields, segment margins, and goodwill impacts with one-click Tilray Brands earnings report filing analysis.
- Receive instant notice when a director files Tilray Brands insider trading Form 4 transactions or when new equity is issued.
- Compare compensation packages straight from the latest Tilray Brands proxy statement executive compensation section.
Whether you are understanding Tilray Brands SEC documents with AI for valuation models or following Tilray Brands executive stock transactions Form 4 before earnings, every filing is organized, searchable, and linked to expert context. Complex disclosures become actionable so you can focus on investment decisions, not document digging.
Exelixis (EXEL) posted mixed Q2 2025 results. Net product revenue rose 19% YoY to $520.0 m on continued CABOMETYX growth, lifting six-month product sales 27% to $1.03 b. However, the absence of last year鈥檚 $150 m Ipsen milestone drove collaboration revenue down 76% to $48.3 m, pulling total quarterly revenue to $568.3 m (-11%). Operating expenses were flat; yet operating income fell 23% to $213.6 m and net income slid 18% to $184.8 m, or $0.65 diluted EPS (vs $0.77).
Year-to-date momentum remains solid. For the first six months, revenue climbed 6% to $1.12 b and net income jumped 31% to $344.5 m ($1.20 EPS) thanks to stronger U.S. product demand and lower restructuring charges. Operating cash flow improved 38% to $260.4 m.
Capital allocation and balance sheet. The company repurchased 21.7 m shares for $796 m, trimming cash and investments to $1.38 b (-21% YTD) and reducing shares outstanding to 270.1 m. Equity compensation expense was $62 m (+39%).
Pipeline & legal. EXEL settled with Biocon, deferring U.S. generic entry until 1 Jan 2031. ANDA challenges from MSN, Sun and Azurity continue; recent Delaware rulings upheld key patents through 2030, but appeals are pending. R&D spend fell 5% to $200.4 m as the phase 3 zanzalintinib program advances.
Key metrics Q2 2025 vs Q2 2024:
- Total revenue $568.3 m vs $637.2 m
- Product gross margin ~96%
- GAAP EPS $0.65 vs $0.77
- Cash & investments $1.39 b
Tilray Brands (Nasdaq: TLRY) filed a Form 8-K reporting a private debt-for-equity exchange completed on June 16 2025 under Item 3.02.
The company exchanged $5 million principal of its 5.20% Convertible Senior Notes due 2027 for 12,591,816 newly issued common shares. The transaction was executed with a single, unrelated holder and relied on the Securities Act Section 3(a)(9) exemption, so the shares were issued without SEC registration and no commissions were paid.
The exchange immediately reduces outstanding debt and future interest expense but increases the public float, creating potential dilution for existing shareholders. The disclosed figures imply an exchange price of roughly $0.40 per share, though the filing does not comment on market pricing.
No other material events, financial statements, legal proceedings, or risk factors were included in this report.
FAQ
What is the current stock price of TILRAY BRANDS (TLRY)?
What is the market cap of TILRAY BRANDS (TLRY)?
What is Tilray Brands Inc.?
How does Tilray generate revenue?
What makes Tilray different from other cannabis companies?
Which markets does Tilray serve?
What are the core business segments of Tilray?
How does Tilray ensure the quality and safety of its products?
